Tocol mitocans have previously been demonstrated to sensitize NB cells to chemotherapeutics by several mechanisms [49,51], including potent inhibition of MYCN expression driving the aggressive clinical behavior and poor therapeutic response in high-risk disease [59]. Here, MYCN is linked to neuroblastoma.